KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Change in Working Capital (2016 - 2026)

Teva Pharmaceutical Industries filings provide 10 years of Change in Working Capital readings, the most recent being -$617.0 million for Q1 2026.

  • On a quarterly basis, Change in Working Capital rose 11.86% to -$617.0 million in Q1 2026 year-over-year; TTM through Sep 2017 was -$755.0 million, a 168.64% decrease, with the full-year FY2025 number at -$1.4 billion, down 214.02% from a year prior.
  • Change in Working Capital hit -$617.0 million in Q1 2026 for Teva Pharmaceutical Industries, up from -$700.0 million in the prior quarter.
  • In the past five years, Change in Working Capital ranged from a high of -$617.0 million in Q1 2026 to a low of -$700.0 million in Q1 2025.